Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer With Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]

NCT03421652 is registered in ClinicalTrials.gov with Barbara Ann Karmanos Cancer Institute as lead sponsor.

NCT NCT03421652
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03421652 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Trial of Concurrent Nivolumab in Urothelial Bladder Cancer With Radiation Therapy in Localized/Locally Advanced Disease for Chemotherapy Ineligible Patients [NUTRA]
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Phase
Phase 2
Overall status
Completed
Start date
April 24, 2018
Completion date
March 23, 2023
Enrollment
20 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

stage ii bladder urothelial carcinoma ajcc v6 and v7, stage iii bladder urothelial carcinoma ajcc v6 and v7, stage iv bladder urothelial carcinoma ajcc v7